רווח למניה בשנים עשר החודשים האחרונים: Equillium Bio (EQ)

Equillium, Inc. (EQ) is developing advanced immunotherapy that curbs inflammation by blocking T-cell receptors without inducing systemic immunosuppression. TTM net income per share illustrates the dynamics of this process, where the value of -0.18 corresponds to the current metric. Fundamentals are supported by the development of itaolizumab to combat GVHD and the availability of certified laboratories conducting regular preclinical tests.

The selection of high-quality issuers is based on an analysis of profit generation efficiency through a system of fundamental multiples. This indicator determines the specific net income over a rolling year, normalizing total income relative to the total number of shares. For Equillium, Inc. (EQ), this calculation confirms stability driven by grants and partnerships that offset R&D costs. Analyzing the dynamics of rolling net income per share allows for an assessment of business adaptability; however, the stability of the curve may mask the risk of an overvalued stock.